Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05244551 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Abbisko Therapeutics Co.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
- 20
- Study locations
NCT05244551: Recruiting Phase 1 study of Solid Tumor, sponsored by Abbisko Therapeutics Co.
NCT05244551 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Abbisko Therapeutics Co. The registered enrollment target is 85 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05244551, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Abbisko Therapeutics Co.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK061 administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK061 at the recommended dose for expansion (RDE) to further evaluate safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.
Conditions Studied
Interventions
- DRUG ABSK061
Study Locations (20)
Henan
- Henan Cancer Hospital - Zhengzhou
- The First Affiliated Hospital of Zhengzhou University - Zhengzhou
Jilin
- First Hospital of Jilin University - Changchun
- JILIN Cancer Hospital - Changchun
Liaoning
- Liaoning Province Cancer Hospital - Shenyang
- The First Hospital of China Medical University - Shenyang
Texas
- Mary Crowley Cancer Research - Dallas
Abbisko Therapeutics Co., Ltd. 12B Floor, Building 1, Lane 515
- Yuan LU - Shanghai
Anhui
- The First Affiliated Hospital of Bengbu Medical College - Bengbu
Beijing Municipality
- Cancer Hospital Chinese Academy of Medical Sciences - Beijing
Chongqing Municipality
- Chongqing Daping Hospital - Chongqing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2022-06-30 |
| Est. Completion | 2025-04-30 |
| Phase | Phase 1 |
What NCT05244551 shows while recruiting
NCT05244551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ABSK061 is the first listed.
NCT05244551 names 20 study sites across 17 states, led by Henan, Jilin, Liaoning.
Frequently Asked Questions
What is clinical trial NCT05244551 about?
NCT05244551 is a clinical study titled "A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors". This is an open-label phase 1 study with expansion. The study will start with a dose escalation of single-agent ABSK061 administered in repeated 28-day cycles in patients with advanced solid tumors to evaluate safety and tolerability. The expansion part will investigate oral ABSK061 at the recommend...
What is the current status of trial NCT05244551?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2022-06-30. Estimated completion is 2025-04-30.
What conditions does trial NCT05244551 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT05244551?
The interventions under investigation include: ABSK061 (DRUG).
Who is sponsoring clinical trial NCT05244551?
This trial is sponsored by Abbisko Therapeutics Co, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05244551 being conducted?
This trial has 20 study locations across Texas, Abbisko Therapeutics Co., Ltd. 12B Floor, Building 1, Lane 515, Anhui, Beijing Municipality, Chongqing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05244551's enrollment target sits among peer trials
85 95th of 196 higher than 101 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI